The average of price targets set by Wall Street analysts indicates a potential upside of 231.8% in Promis Neurosciences (PMN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Ally Bridge Group NY LLC increased its position in Promis Neurosciences (NASDAQ: PMN) by 367.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,233,497 shares of the company's stock after buying an additional 4,899,069 shares during the quarter. Promis Neurosciences